1 |
Communiqué |
text |
2 |
T40 |
text |
3 |
How to Advertise |
text |
4 |
Privacy and cookies |
text |
5 |
My Account |
text |
6 |
Register |
text |
7 |
I have forgotten my pa***word |
text |
8 |
- |
image |
9 |
PME |
image |
10 |
Communiqué |
image |
11 |
T40 |
image |
12 |
Digital, doctors and patients |
image |
13 |
- |
image |
14 |
Advanced search |
text |
15 |
Home |
text |
16 |
News |
text |
17 |
COVID-19 |
text |
18 |
Intelligence |
text |
19 |
Thought Leaders***p |
text |
20 |
Appointments |
text |
21 |
Awards |
text |
22 |
Blogs |
text |
23 |
Top Pharma List |
text |
24 |
T 40 |
text |
25 |
PMHub |
text |
26 |
Interview with Novo Nordisk's Ludovic Helfgott |
text |
27 |
Five pharma leaders to watch in 2020 |
text |
28 |
Tackling antimicrobial resistance |
text |
29 |
The changing nature of approvals |
text |
30 |
COVID-19 round-up: medicines on trial |
text |
31 |
- |
image |
32 |
FDA gives green light to Merck/MSD’s antibiotic drug Recarbrio |
text |
33 |
- |
image |
34 |
Imperial College London pledges low-cost access to COVID-19 vaccine |
text |
35 |
- |
image |
36 |
Lundbeck axes staff in revamp of its R&D |
text |
37 |
- |
image |
38 |
Report that AstraZeneca approached Gilead about a possible merger |
text |
39 |
- |
image |
40 |
Sales news |
text |
41 |
Coronavirus disruption scuppers Curium Pharma sale |
text |
42 |
Did Trump offer CureVac $1bn for COVID-19 vaccine rights? |
text |
43 |
Lilly joins new Medicare scheme to reduce insulin prices |
text |
44 |
Research news |
text |
45 |
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs |
text |
46 |
New study identifies drugs that are safe to use in COVID-19 treatment |
text |
47 |
J&J says COVID-19 vaccine could be ready in early 2021 |
text |
48 |
- |
image |
49 |
Q&A: Kay Wesley |
text |
50 |
Marketing news |
text |